Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | PTPRB | P23467 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097237 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2CA1CA2ZDHHC7MME | |
| SCHEMBL11665740 | 0.82 | CA1 (0.44) | SMN1; SMN2CA1CA2ZDHHC7MME | |
| SCHEMBL2779128 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2MGAMGAASIMGAM2 | |
| SCHEMBL3883424 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2CA1CA2ZDHHC7MME | |
| SCHEMBL11347511 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2CA1CA2ZDHHC7MME | |
| SCHEMBL69910 | 0.79 | — | — | |
| SCHEMBL11482438 | 0.79 | CA2 (0.55) | CA1CA2ZDHHC7ALDH1A1TSHR | |
| SCHEMBL222338 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2CA1CA2ZDHHC7MME | |
| SCHEMBL29057718 | 0.77 | TSHR (0.37) | TSHR | |
| SCHEMBL2564479 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2CA1CA2ZDHHC7MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112851494-B | Preparation method of 1-pyrene butyric acid | 苏州昊帆生物股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-112851494-A | Preparation method of 1-pyrenebutyric acid | 苏州昊帆生物股份有限公司 | 2021-05-28 | — | — | CN | claimed |
| CN-112851494-B | Preparation method of 1-pyrene butyric acid | 苏州昊帆生物股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-112851494-A | Preparation method of 1-pyrenebutyric acid | 苏州昊帆生物股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-2427430-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127452-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010091226-A1 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION | RESOLVYX PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2008-09-04 | — | — | US | disclosed |
| US-7375252-B2 | Compounds and method for the inhibition of the expression of VCAM-1 | ATHEROGENICS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7189870-B2 | Compounds and methods for the inhibition of the expression of VCAM-1 | ATHEROGENIC, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1726582-A2 | Compounds and methods for the inhibition of the expression of vcam-1 | Atherogenics, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-0652208-B1 | Phenylalkan(en)oic acids with leukotriene B4 antagonistic activity | ONO PHARMACEUTICAL CO (JP) | 1998-01-14 | — | — | EP | disclosed |
| US-5457122-A | Leukotriene antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| EP-0652208-A1 | Phenylalkan(en)oic acids with leukotriene B4 antagonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-5256686-A | Antiinflammatory agent, antiallergens | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| US-5155104-A | Phenylalkan(en)oic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-5086065-A | Leukotriene antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0405116-A2 | Phenylalkan(en)oic acids | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-01-02 | — | — | EP | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
| US-4123610-A | Nucleic acid crosslinking agent and affinity inactivation of nucleic acids therewith | THE UNITED STATES GOVERNMENT (US) | 1978-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | VCAM1, ICAM1, SELL | SMN1; SMN2 3786/4885CA1 2976/4885CA2 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.